B Group Inc. Takes $388,000 Position in Oruka Therapeutics, Inc. (NASDAQ:ORKA)

B Group Inc. bought a new position in Oruka Therapeutics, Inc. (NASDAQ:ORKA) during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm bought 20,000 shares of the company’s stock, valued at approximately $388,000. Oruka Therapeutics comprises about 0.2% of B Group Inc.’s investment portfolio, making the stock its 17th biggest position. B Group Inc. owned approximately 0.06% of Oruka Therapeutics as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other hedge funds also recently bought and sold shares of ORKA. FMR LLC grew its position in shares of Oruka Therapeutics by 17.7% in the 4th quarter. FMR LLC now owns 5,512,300 shares of the company’s stock worth $106,883,000 after buying an additional 830,000 shares during the last quarter. Vanguard Group Inc. lifted its stake in Oruka Therapeutics by 4,161.2% in the fourth quarter. Vanguard Group Inc. now owns 1,610,651 shares of the company’s stock worth $31,231,000 after acquiring an additional 1,572,853 shares during the period. Franklin Resources Inc. bought a new stake in Oruka Therapeutics in the third quarter valued at $17,661,000. SR One Capital Management LP increased its position in Oruka Therapeutics by 14.7% during the 4th quarter. SR One Capital Management LP now owns 430,330 shares of the company’s stock valued at $8,344,000 after purchasing an additional 55,000 shares during the period. Finally, Affinity Asset Advisors LLC increased its position in Oruka Therapeutics by 5.4% during the 4th quarter. Affinity Asset Advisors LLC now owns 368,698 shares of the company’s stock valued at $7,149,000 after purchasing an additional 18,862 shares during the period. Hedge funds and other institutional investors own 56.44% of the company’s stock.

Insider Transactions at Oruka Therapeutics

In other Oruka Therapeutics news, major shareholder Venrock Healthcare Capital Par bought 88,794 shares of Oruka Therapeutics stock in a transaction on Friday, February 14th. The stock was acquired at an average price of $11.44 per share, with a total value of $1,015,803.36. Following the acquisition, the insider now owns 4,148,428 shares in the company, valued at approximately $47,458,016.32. This trade represents a 2.19 % increase in their ownership of the stock. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Over the last 90 days, insiders have bought 98,339 shares of company stock worth $1,128,456. Corporate insiders own 22.67% of the company’s stock.

Oruka Therapeutics Trading Up 7.0 %

Oruka Therapeutics stock opened at $9.22 on Monday. Oruka Therapeutics, Inc. has a 12 month low of $5.49 and a 12 month high of $31.13. The company has a market capitalization of $345.02 million, a price-to-earnings ratio of -1.47 and a beta of 0.47. The business’s fifty day simple moving average is $10.15 and its two-hundred day simple moving average is $17.26.

Oruka Therapeutics (NASDAQ:ORKA) last posted its quarterly earnings results on Thursday, March 6th. The company reported ($0.49) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.68) by $0.19. On average, equities research analysts predict that Oruka Therapeutics, Inc. will post -3.41 EPS for the current year.

Analyst Upgrades and Downgrades

ORKA has been the subject of several research analyst reports. HC Wainwright reaffirmed a “buy” rating and set a $45.00 target price on shares of Oruka Therapeutics in a research note on Friday, February 7th. Wedbush reaffirmed an “outperform” rating and set a $40.00 price objective on shares of Oruka Therapeutics in a research report on Friday, March 7th. Finally, Wolfe Research initiated coverage on Oruka Therapeutics in a research report on Tuesday, February 4th. They issued an “outperform” rating and a $20.00 target price for the company. Seven research analysts have rated the stock with a buy rating and two have issued a strong buy rating to the company. According to data from MarketBeat, the company presently has an average rating of “Buy” and an average price target of $39.86.

Oruka Therapeutics Profile

Oruka Therapeutics, Inc is a biotechnology company, which focuses on developing novel monoclonal antibody therapeutics for PsO and other I&I indications. Its pipeline includes ORKA-001 and ORKA-002. The company is headquartered in Menlo Park, CA.